Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 15, 2019
Pharmacy Choice - News - Front Page Healthcare News - February 15, 2019

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/15/19 - 5 rural Maine hospitals, including one in bankruptcy, will get expert help to run sustainably [Bangor Daily News, Maine]
Penobscot Valley Hospital in Lincoln, Northern Light C.A. Dean Hospital in Greenville, Northern Light Sebasticook Valley Hospital in Pittsfield, Mayo Regional Hospital in Dover-Foxcroft and Calais Regional Hospital are among 25 hospitals in the nation that have won the award from the federal Office of Rural Health Policy. The award entitles them to
2/15/19 - A Dose-response Study to Examine the Cholesterol-lowering Effects of Canned Mixed Beans
By a News Reporter-Staff News Editor at Clinical Trials Week Staff editors report on the newly launched clinical trial, NCT03830970, which has the following summary description: "The Bean Study will examine the effects of consuming varying doses of canned mixed beans on blood cholesterol levels in healthy adults with elevated blood cholesterol le
2/15/19 - A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of Troriluzole in Generalized Anxiety Disorder
By a News Reporter-Staff News Editor at Clinical Trials Week Staff editors report on the newly launched clinical trial, NCT03829241, which has the following summary description: "The purpose of this study is to compare the efficacy of BHV-4157 versus placebo in subjects with Generalized Anxiety Disorder." As a matter of record, on February 5, 201
2/15/19 - A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of JTE-451 Administered for 16 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)
By a News Reporter-Staff News Editor at Clinical Trials Week Staff editors report on the newly launched clinical trial, NCT03832738, which has the following summary description: "Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis." As a matter of record, on February
2/15/19 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
By a News Reporter-Staff News Editor at Clinical Trials Week Staff editors report on the newly launched clinical trial, NCT03831191, which has the following summary description: "The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis." As a matter of record, on Feb
2/15/19 - A Phase 1, Double-Blinded, Placebo Controlled, Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of HEV-239 (Hecolin) in a Healthy US Adult Population
By a News Reporter-Staff News Editor at Health& Medicine Week Staff editors report on the newly launched clinical trial, NCT03827395, which has the following summary description: "This is a Phase I double-blind, randomized, placebo controlled trial of Hepatitis E virus vaccine containing a 239 amino acid subfragment of Hecolin in 25 US males a
2/15/19 - A Phase 1, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944, Encoding for an Anti-Chikungunya Virus Monoclonal Antibody, in Healthy Adults
By a News Reporter-Staff News Editor at Virus Weekly Staff editors report on the newly launched clinical trial, NCT03829384, which has the following summary description: "This is a Phase 1, FIH, single-center, randomized, placebo controlled, dose escalation study to evaluate the safety, tolerability, PK, and PD of a single dose of mRNA 1944 in he
2/15/19 - A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a Kras Mutation
By a News Reporter-Staff News Editor at Cancer Vaccine Week Staff editors report on the newly launched clinical trial, NCT03829410, which has the following summary description: "The purpose of the Phase 1 b/2 study is to determine the safety and efficacy of Onvansertib, administered orally, daily, for 5 consecutive days on Day 1-5 of each 14- day
2/15/19 - A Phase II Study Evaluating the Safety and Efficacy of Umbralisib (TGR-1202) in Combination With Ublituximab in Patients With Treatment Naive Follicular Lymphoma and Small Lymphocytic Lymphoma
By a News Reporter-Staff News Editor at Clinical Oncology Week Staff editors report on the newly launched clinical trial, NCT03828448, which has the following summary description: "This is a phase 2, open label study to assess umbralisib in combination with ublituximab in subjects with treatment naive Follicular Lymphoma and Small Lymphocytic Lym
2/15/19 - A Pilot Study of 68Ga-RM2 PET/MRI in the Evaluation of Patients With Estrogen Receptor-Positive Breast Cancer
By a News Reporter-Staff News Editor at Cancer Weekly Staff editors report on the newly launched clinical trial, NCT03831711, which has the following summary description: "This trial studies how well 68 Ga-RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68 Ga-RM2 is an agent used in diagnostic imaging.
2/15/19 - A Randomised Controlled Trial to Study the Efficacy and Safety of TIPS (Trans Intrahepatic Portosystemic Shunt) Versus Self Expanding Metallic Stent (SEMS) in the Management of Refractory Variceal Bleed in Cirrhotics
By a News Reporter-Staff News Editor at Health& Medicine Week Staff editors report on the newly launched clinical trial, NCT03827681, which has the following summary description: "A total of 50 patients will be enrolled and will be randomized into either Group A or Group B. Primary end point of the study will be to compare efficacy of TIPS versus
2/15/19 - A Randomized Double-Blind Study of Adjuvant Pembrolizumab or Placebo in Patients With MSI-H Tumors With Persistent Circulating Tumor DNA Following Surgery
By a News Reporter-Staff News Editor at Cancer Vaccine Week Staff editors report on the newly launched clinical trial, NCT03832569, which has the following summary description: "The purpose of this study is to test the safety of the study drug, pembrolizumab, and to find out how well it works to prevent cancer from coming back in people who have
2/15/19 - A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa
By a News Reporter-Staff News Editor at Health& Medicine Week Staff editors report on the newly launched clinical trial, NCT03827798, which has the following summary description: "The main purpose of this study is to assess preliminary efficacy and safety of CFZ533 and LYS006 in patients with moderate to severe hidradenitis suppurativa and to det
2/15/19 - Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has submitted a continuation patent application with U.S. Patent and Trademark Office to broaden the claims relating to the use of AD04 for opioid dependence and abuse, commonly referred to as Opio
2/15/19 - Advanced Infusion Systems Share - Industry Size, Growth Report & Forecast - 2026: AngioDynamics, Inc., Animas Corporation, B. Braun Melsungen AG, Terumo Corpora: Overall increase in global population suffering from chronic disease, cancer, diabetes i
Valley Cottage, NY 02/15/2019 Infusion systems are medical instruments and associated disposables, used to deliver fluids or drugs in solution to patient's circulatory system in a controlled, precise and automated manner. There are different routes to introduce a drug into the patient's system, of which, highly used mode is through intravenou
2/15/19 - Agency Information Collection Activities; Proposed Collection; Comment Request; Reporting Associated With New Animal Drug Applications and Veterinary Master Files
Agency: " Food and Drug Administration, HHS." Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the no
2/15/19 - Aledade and Humana Announce Agreement Expanding Value-Based Care for Humana Medicare Advantage Members in Three States
By a News Reporter-Staff News Editor at Managed Care Weekly Digest Aledade, Inc. and leading health and well-being company Humana Inc. announced a value-based care agreement to broaden the availability of coordinated, quality care for Humana Medicare Advantage members in three states. Through this agreement, physicians in Aledade's Accountable Ca
2/15/19 - ALKERMES PLC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations
The following should be read in conjunction with our consolidated financial statements and related notes beginning on page F 1 of this Annual Report. We earn revenue on net sales of VIVITROL, ARISTADA and ARISTADA INITIO, which are proprietary products that we manufacture, market and sell in the U.S., and manufacturing and/or royalty revenues on
2/15/19 - An Open-Label Phase 1 Study of Metformin in Combination With Nelfinavir in Patients With Relapsed and/or Refractory Multiple Myeloma
By a News Reporter-Staff News Editor at Anti-Infectives Week Staff editors report on the newly launched clinical trial, NCT03829020, which has the following summary description: "This phase I trial studies the side effects and best dose of metformin and nelfinavir in treating patients with multiple myeloma that has come back or does not respond t
2/15/19 - An Open-label, Dose Escalation Study in Japanese Subjects With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
By a News Reporter-Staff News Editor at Cardiovascular Week Staff editors report on the newly launched clinical trial, NCT03828292, which has the following summary description: "GSK2857916 is a first in class, antibody dependent cellular cytotoxicity enhanced, humanized immunoglobulin G1 antibody-drug conjugate which binds specifically to B cell.
2/15/19 - App Bridges Technology Gap and Disrupts Barriers to Patient Engagement
Imagine having years of your medical history available at your fingertips securely. The Health and Human Services has called for new standards issued by the Centers for Medicare and Medicaid Services and the Office of the National Coordinator for Health Information Technology in securely sharing patient data across systems. When veteran healthcar
2/15/19 - Astellas and Affinivaxs novel pneumococcal vaccine enters human testing [T-break Tech (Middle East)]
About two years ago, Astellas licensed a novel pneumococcal vaccine technology from Affinivax with eyes on Pfizers Prevnar 13. The first patient has been dosed with the investigational vaccine, dubbed ASP3772, in a phase 1/ 2 study that aims to evaluate the vaccines safety, tolerability and immunogenicity, Affinivax said on Wednesday. We believe th
2/15/19 - Atherectomy Devices Market Is Estimated To Reach $894.69 Million By 2025: Grand View Research, Inc.
According to report published by Grand View Research, The demand for atherectomy devices market is anticipated to boost over the forecast period due to rapidly rising incidence of target diseases such as peripheral artery disease.New technologies and product approvals are expected to boost the market for orbital and laser atherectomy devices over t
2/15/19 - Audit: MCO contracts did not protect state State audit says behavioral health MCO contracts did not protect state interests
A state audit released Thursday found that the contracts of North Carolina's seven behavioral health managed care organizations contracts were not precise enough to fully protect state and federal interests. Auditors determined N.C. Department of Health and Human Services' contracts with the organizations "did not always contain clear contractual..
2/15/19 - Avapritinib receives Phase III clinical trial approval for GIST in China
CStone Pharmaceuticals today announced that the National Medical Products Administration recently approved a Phase III clinical trial in China for its partnered drug candidate avapritinib as a third-line treatment against KIT-driven gastrointestinal stromal tumors. According to data from the NAVIGATOR Phase I clinical trial reported as of October
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2019 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415